Want to see ZCMD full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Strong Equity Position
A strong equity position with low leverage provides Zhongchao with a stable financial foundation, reducing risk and enhancing resilience against market fluctuations.
Negative Factors
Declining Revenues
Declining revenues can hinder growth and profitability, impacting Zhongchao's ability to invest in new opportunities and maintain competitive positioning.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Position
A strong equity position with low leverage provides Zhongchao with a stable financial foundation, reducing risk and enhancing resilience against market fluctuations.
Read all positive factors
Zhongchao (ZCMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.34M
Dividend YieldN/A
Average Volume (3M)69.01K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue Growth-28.30%
EPS Growth-86.74%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,149,825
10 Day Avg. Volume16,721
30 Day Avg. Volume69,011
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.66
Price to Sales (P/S)1.08
P/FCF Ratio17.76
Enterprise Value/Market Cap-3.43
Enterprise Value/Revenue-0.70
Enterprise Value/Gross Profit-1.61
Enterprise Value/Ebitda1.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhongchao Business Overview & Revenue Model
Company Description
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs...
How the Company Makes Money
Zhongchao Inc. generates revenue primarily through its Medical Training and Education segment by offering training programs to healthcare professionals, which include online courses, workshops, and seminars. These programs are often developed in c...
Zhongchao Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.37M | 15.86M | 19.43M | 14.15M | 16.30M |
| Gross Profit | 4.83M | 8.91M | 8.51M | 6.36M | 9.44M |
| EBITDA | -5.45M | 87.95K | -4.49M | -1.82M | 592.22K |
| Net Income | -6.31M | -643.23K | -11.34M | -2.94M | 238.66K |
Balance Sheet | |||||
| Total Assets | 24.32M | 25.88M | 24.42M | 38.61M | 36.27M |
| Cash, Cash Equivalents and Short-Term Investments | 13.92M | 13.08M | 13.45M | 12.04M | 14.21M |
| Total Debt | 26.08K | 57.52K | 808.16K | 1.70M | 201.56K |
| Total Liabilities | 1.72M | 1.73M | 3.38M | 5.60M | 3.70M |
| Stockholders Equity | 18.63M | 20.84M | 18.01M | 29.93M | 32.57M |
Cash Flow | |||||
| Free Cash Flow | 692.83K | -4.52M | -785.51K | -2.52M | 1.06M |
| Operating Cash Flow | 845.39K | -1.47M | 54.23K | -661.74K | 2.86M |
| Investing Cash Flow | -826.60K | -1.81M | -3.75M | -3.35M | -4.02M |
| Financing Cash Flow | 0.00 | 3.84M | 0.00 | 1.85M | 0.00 |
Zhongchao Technical Analysis
Negative
2.06
Price Trends
67.44
Negative
119.33
Negative
297.82
Negative
Market Momentum
-15.18
Negative
17.96
Positive
59.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZCMD, the sentiment is Negative. The current price of 2.06 is above the 20-day moving average (MA) of 1.70, below the 50-day MA of 67.44, and below the 200-day MA of 297.82, indicating a neutral trend. The MACD of -15.18 indicates Negative momentum. The RSI at 17.96 is Positive, neither overbought nor oversold. The STOCH value of 59.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZCMD.
Zhongchao Risk Analysis
Zhongchao disclosed 77 risk factors in its most recent earnings report. Zhongchao reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zhongchao Peers Comparison
UnderperformOutperform
Sector (51)
ZCMD
Zhongchao
2.03
-846.13
-99.76%
SCNX
Scienture Holdings
0.37
-1.28
-77.58%
ONMD
OneMedNet
0.76
0.21
38.55%
VSEE
VSee Health
0.11
-1.27
-91.96%
MGRX
Mangoceuticals, Inc.
0.37
-1.16
-75.99%
Zhongchao Corporate Events
Zhongchao Inc. Faces Nasdaq Compliance Challenge
Dec 1, 2025
Zhongchao Inc. received a notification from Nasdaq on November 28, 2025, regarding non-compliance with the Minimum Bid Price Requirement, as its Class A ordinary shares had closed below $1.00 per share from October 9 to November 26, 2025. The comp...
Zhongchao Inc. Announces Extraordinary General Meeting for January 2026
Nov 26, 2025
Zhongchao Inc. has announced an extraordinary general meeting of its Class A ordinary shareholders to be held on January 20, 2026, in New York. The meeting will address two key proposals: a special resolution to increase the voting rights of Class...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―